AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27751214 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 35
Study 25732262 — intervention group
Group type: EXPERIMENTAL
Intervention: VISCODERM Pearls (dietary supplement) administered 2 times a day for 4 weeks
Number of subjects: 30
Study 25732262 — intervention group
Group type: EXPERIMENTAL
Intervention: VISCODERM Pearls (dietary supplement)
Number of subjects: 30
Study 25732262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22426799 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongyan spray
Number of subjects: 122
Study 22426799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 20032972 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 1.4 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15
Study 20032972 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 2.8 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15
Study 20032972 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh containing 5.6 mg of 23‐epi‐26‐deoxyactein
Number of subjects: 15
Study 20032972 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% ethanol extract of black cohosh
Number of subjects: 15
Study 18338955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin, 0.4 mg once daily (Group A)
Number of subjects: 75
Study 18338955 — intervention group
Group type: COMPARATOR
Intervention: No alpha(1)-blocker (Group B, control group)
Number of subjects: 75
Study 15975174 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soya protein (ISP) containing 68 mg/d soy isoflavones (genistein, daidzein, equol)
Number of subjects: 23
Study 15975174 — intervention group
Group type: COMPARATOR
Intervention: Milk protein placebo
Number of subjects: 23
Study 12701051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nervous blockade with local anesthesia
Number of subjects: 10
Study 12701051 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no nervous blockade)
Number of subjects: 10
Study 10230667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial colour-coded duplex sonography (TCCS) in craniosynostosis group
Number of subjects: 21
Study 10230667 — intervention group
Group type: COMPARATOR
Intervention: Transcranial colour-coded duplex sonography (TCCS) in healthy control group
Number of subjects: 21
Study 8744872 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion activities
Number of subjects: 0
Study 8744872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition- and exposure-related activities
Number of subjects: 0
Study 8744872 — intervention group
Group type: EXPERIMENTAL
Intervention: Employer changes to reduce exposures to occupational hazards
Number of subjects: 0
Study 1921739 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg oestriol (E3) vaginal suppository, administered twice weekly for 3 weeks, then weekly for 6 months
Number of subjects: 109
Study 1921739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 344105 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum
Number of subjects: 22
Study 344105 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 22
Study 31126016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine content (no, low, high)
Number of subjects: 706
Study 31126016 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor (menthol, tobacco, fruit)
Number of subjects: 706
Study 31126016 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified risk message (reduced harm, reduced carcinogen exposure)
Number of subjects: 706
Study 31126016 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater nicotine content, tobacco-flavored and reduced carcinogen exposure ECIGs
Number of subjects: 706
Study 28774251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal extensor tendon-splitting approach
Number of subjects: 32
Study 28774251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal extensor tendon-reflecting approach
Number of subjects: 32
Study 28774251 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar A1 pulley approach
Number of subjects: 32
Study 28774251 — intervention group
Group type: COMPARATOR
Intervention: Dorsal approaches
Number of subjects: 32
Study 26345270 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measurement-based care (MBC) implementation
Number of subjects: 0
Study 26345270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored measurement-based care (MBC) implementation
Number of subjects: 0
Study 26345270 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care fidelity
Number of subjects: 0
Study 23525931 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately preterm children (MP)
Number of subjects: 988
Study 21457883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 mg cetirizine (CET) and 120 mg pseudoephedrine (PSE)
Number of subjects: 70
Study 21457883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19825188 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 114
Study 19825188 — intervention group
Group type: COMPARATOR
Intervention: rLH
Number of subjects: 114
Study 16148617 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 36
Study 16148617 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg)
Number of subjects: 36
Study 12970202 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 611
Study 12970202 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611
Study 12970202 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical
Number of subjects: 611
Study 12970202 — intervention group
Group type: COMPARATOR
Intervention: AMI
Number of subjects: 611
Study 12970202 — intervention group
Group type: COMPARATOR
Intervention: Coronary Angiograms
Number of subjects: 611
Study 10574302 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling sessions
Number of subjects: 396
Study 10574302 — intervention group
Group type: COMPARATOR
Intervention: Individual counseling sessions
Number of subjects: 396
Study 10574302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment motivation
Number of subjects: 396
Study 8845685 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily levobunolol 0.5%
Number of subjects: 25
Study 8845685 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice-daily
Number of subjects: 25
Study 8845685 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% once-daily
Number of subjects: 25
Study 2347325 — intervention group
Group type: EXPERIMENTAL
Intervention: Test C (decreased calf volume by lifting calves 40 cm above heart level)
Number of subjects: 6
Study 2347325 — intervention group
Group type: COMPARATOR
Intervention: Test A (resting in exercise position)
Number of subjects: 6
Study 2347325 — intervention group
Group type: COMPARATOR
Intervention: Test B (increased calf volume by venous congestion)
Number of subjects: 6
Study 637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia and operation
Number of subjects: 0
Study 637296 — intervention group
Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 0
Study 637296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow conditions
Number of subjects: 0
Study 29537449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.5% QD
Number of subjects: 356
Study 29537449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.0% QD
Number of subjects: 356
Study 29537449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.5% QD
Number of subjects: 356
Study 29537449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.0% BID
Number of subjects: 356
Study 29537449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 1.5% BID
Number of subjects: 356
Study 29537449 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 356
Study 27920515 — intervention group
Group type: EXPERIMENTAL
Intervention: ELOM-080 (3×300 mg)
Number of subjects: 64
Study 27920515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24285617 — intervention group
Group type: EXPERIMENTAL
Intervention: daily acute intermittent hypoxia (dAIH)
Number of subjects: 19
Study 24285617 — intervention group
Group type: EXPERIMENTAL
Intervention: dAIH + walking
Number of subjects: 19
Study 24285617 — intervention group
Group type: COMPARATOR
Intervention: daily normoxia (dSHAM)
Number of subjects: 19
Study 22717153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation (0.2 g, 0.3 g, 0.4 g, 0.5 g, and 0.6 g from day 4 to 28)
Number of subjects: 50
Study 22717153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 50
Study 22717153 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 20406355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough surface with microthread implants (Hexplant)
Number of subjects: 54
Study 20406355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface implants (TiUnite)
Number of subjects: 54
Study 20406355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid surface implants (Restore)
Number of subjects: 54
Study 18312123 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attachment priming
Number of subjects: 169
Study 18312123 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attachment priming
Number of subjects: 169
Study 18312123 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral attachment priming
Number of subjects: 169
Study 18312123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no priming)
Number of subjects: 169
Study 16109990 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (annual application)
Number of subjects: 0
Study 16109990 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride varnish
Number of subjects: 0
Study 12145176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/day)
Number of subjects: 15
Study 12145176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9931168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive drugs
Number of subjects: 78
Study 9931168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 78
Study 9931168 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 78
Study 9931168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilation with combination treatment
Number of subjects: 78
Study 9931168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilation with nifedipine
Number of subjects: 78
Study 9931168 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-independent dilation with hydrochlorothiazide
Number of subjects: 78
Study 7474028 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment reminder call (TC)
Number of subjects: 80
Study 7474028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reminder call (TC) and satisfaction questionnaire
Number of subjects: 80
Study 2193261 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intravaginal clindamycin phosphate (0.1%, 1.0%, and 2.0%)
Number of subjects: 62
Study 2193261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2193261 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intravaginal clindamycin phosphate (1.0%)
Number of subjects: 62
Study 471856 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (5 mg i.v.)
Number of subjects: 0
Study 471856 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (5 mg i.v.) with apomorphine (0.25 mg i.v.)
Number of subjects: 0
Study 31015124 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroma presence (visible/highly visible)
Number of subjects: 1149
Study 31015124 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 1149
Study 31015124 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger tumour size, haematoma, current smoking, and body image concerns at baseline
Number of subjects: 1149
Study 28455465 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 (vitamin E diffused highly cross-linked polyethylene)
Number of subjects: 67
Study 28455465 — intervention group
Group type: COMPARATOR
Intervention: ArComXL (medium cross-linked polyethylene)
Number of subjects: 67
Study 28455465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 67
Study 26075212 — intervention group
Group type: EXPERIMENTAL
Intervention: Music aerobic exercise (MAE) for 12 weeks
Number of subjects: 106
Study 26075212 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no MAE)
Number of subjects: 106
Study 23560810 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy starting immediately after discharge from the hospital
Number of subjects: 200
Study 23560810 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting policy for the first six weeks
Number of subjects: 200
Study 21859215 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepartum motivation measures (global motivation, parenthood motives)
Number of subjects: 0
Study 19037616 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy
Number of subjects: 90
Study 19037616 — intervention group
Group type: COMPARATOR
Intervention: Voice exercise/behavioral treatment
Number of subjects: 90
Study 16963664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs (CXRs) for early detection of lung cancer, performed annually for four years.
Number of subjects: 70000
Study 16963664 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cancer abnormalities observed on CXRs.
Number of subjects: 70000
Study 16963664 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarring/pulmonary fibrosis, cardiac abnormalities, COPD, pleural fluid.
Number of subjects: 70000
Study 12624520 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2, d1) and 5-FU continuous infusion (200 mg/m2/d, d1-21, q3w)
Number of subjects: 50
Study 12624520 — intervention group
Group type: COMPARATOR
Intervention: ECF (epirubicin, cisplatin and 5-FU)
Number of subjects: 50
Study 10726720 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Number of subjects: 383
Study 10726720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 8961576 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided precatheterization information
Number of subjects: 89
Study 8961576 — intervention group
Group type: COMPARATOR
Intervention: Structured precatheterization information
Number of subjects: 89
Study 1550016 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (204 patients)
Number of subjects: 406
Study 1550016 — intervention group
Group type: COMPARATOR
Intervention: Diet B (202 patients)
Number of subjects: 406
Study 2990329 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 081 R.P. (0.2% solution, self-administered intranasally)
Number of subjects: 0
Study 2990329 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment not specified)
Number of subjects: 0
Study 31601170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based childbirth and parenting program (8 classes of 3 hours each, plus 1 day of 7-hour silent meditation)
Number of subjects: 74
Study 31601170 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 74
Study 29276121 — intervention group
Group type: EXPERIMENTAL
Intervention: M2a-Magnum metal-on-metal prosthesis
Number of subjects: 146
Study 29276121 — intervention group
Group type: EXPERIMENTAL
Intervention: ReCap resurfacing metal-on-metal prosthesis
Number of subjects: 146
Study 29276121 — intervention group
Group type: COMPARATOR
Intervention: C2a ceramic-on-ceramic prosthesis
Number of subjects: 146
Study 27658417 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue full dose DMARDs and taper biologic therapy by 50% (Group 1)
Number of subjects: 157
Study 27658417 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper both DMARDs and biologic therapy dose by 50% (Group 2)
Number of subjects: 157
Study 27658417 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper DMARDs by 50% and stop biologic therapy (Group 3)
Number of subjects: 157
Study 27658417 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop both DMARDs and biologic therapy (Group 4)
Number of subjects: 157
Study 27658417 — intervention group
Group type: COMPARATOR
Intervention: Continue medications without change (Group 5)
Number of subjects: 157
Study 24107267 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (O/O)
Number of subjects: 1005
Study 24107267 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by OnabotulinumtoxinA (P/O)
Number of subjects: 1005
Study 24107267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1005
Study 22644348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium vitamin D fortified milk (HCM)
Number of subjects: 63
Study 22644348 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 63
Study 20179328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cueing training for 3 weeks at home using a prototype cueing device
Number of subjects: 153
Study 20179328 — intervention group
Group type: COMPARATOR
Intervention: Control group (late intervention) received cueing training in the following 3 weeks
Number of subjects: 153
Study 17573103 — intervention group
Group type: EXPERIMENTAL
Intervention: Print intervention
Number of subjects: 239
Study 17573103 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 239
Study 17573103 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 239
Study 15964292 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/day NES and 10 microg/day EE (50/10)
Number of subjects: 246
Study 15964292 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/day NES and 20 microg/day EE (50/20)
Number of subjects: 246
Study 15964292 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg/day NES and 15 microg/day EE (150/15)
Number of subjects: 246
Study 15964292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study 11834427 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.03 mU/kg/day)
Number of subjects: 36
Study 11834427 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 10794845 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 98
Study 10794845 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoAI cutoff value of 1.50 g/L
Number of subjects: 98
Study 10794845 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoAI levels
Number of subjects: 98
Study 9289452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy complicated by hypertension
Number of subjects: 62
Study 9289452 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 62
Study 1488158 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation in total parenteral nutrition
Number of subjects: 45
Study 1488158 — intervention group
Group type: COMPARATOR
Intervention: Standard total parenteral nutrition without glutamine
Number of subjects: 45
Study 6499703 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 324
Study 6499703 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 324
Study 6499703 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide treatment in hypokalaemic participants
Number of subjects: 324
Study 30019950 — intervention group
Group type: EXPERIMENTAL
Intervention: E-contact with a female homosexual partner
Number of subjects: 140
Study 30019950 — intervention group
Group type: EXPERIMENTAL
Intervention: E-contact with a male homosexual partner
Number of subjects: 140
Study 30019950 — intervention group
Group type: COMPARATOR
Intervention: E-contact with a heterosexual partner
Number of subjects: 140
Study 28486817 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 54
Study 25304690 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and/or synbiotics administration
Number of subjects: 57
Study 25304690 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 23489778 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training, practicing three WM tasks
Number of subjects: 66
Study 23489778 — intervention group
Group type: COMPARATOR
Intervention: Active control group, practicing three tasks with low WM demand
Number of subjects: 66
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 300
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate dressing
Number of subjects: 300
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Film dressing
Number of subjects: 300
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofiber dressing
Number of subjects: 300
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone dressing
Number of subjects: 300
Study 21999705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin gauze dressing
Number of subjects: 300
Study 17899115 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 984
Study 17899115 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 984
Study 16257098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter dose of ETEC vaccine
Number of subjects: 158
Study 16257098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 16246928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally fluoridated soft water
Number of subjects: 0
Study 16246928 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally fluoridated hard water
Number of subjects: 0
Study 16246928 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially fluoridated soft water
Number of subjects: 0